AbbVie (ABBV) Assets Average (2013 - 2026)
AbbVie (ABBV) posted quarterly Assets Average of $135.2 billion for Q1 2026, little changed year-over-year from $135.7 billion in Q1 2025, and up 0.96% quarter-over-quarter from $133.9 billion in Q4 2025.
AbbVie (ABBV) Assets Average (2013 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Assets Average for 14 consecutive years, with $135.2 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average changed 0.33% year-over-year to $135.2 billion; the TTM figure through Mar 2026 stood at $135.2 billion (changed 0.33% YoY), while the FY2025 annual figure was $134.6 billion, changed 0.28% from the prior year.
- Assets Average improved to $135.2 billion in Q1 2026 per ABBV's latest filing, from $133.9 billion in the prior quarter.
- Across five years, Assets Average topped out at $145.4 billion in Q2 2024 and bottomed at $133.9 billion in Q4 2025.
- Historically, Assets Average has averaged $138.8 billion across 5 years, with a median of $136.7 billion in 2023.
- Annual changes were most pronounced in 2024 — Assets Average gained 7.74% — and 2025, when it slipped 6.01%.
- AbbVie's Assets Average stood at $140.1 billion in 2022, then declined by 3.28% to $135.5 billion in 2023, then grew by 2.82% to $139.3 billion in 2024, then fell by 3.85% to $133.9 billion in 2025, then increased by 0.96% to $135.2 billion in 2026.
- Business Quant data shows ABBV's Assets Average at $135.2 billion in Q1 2026, $133.9 billion in Q4 2025, and $135.5 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 200.98 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 135.79 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 129.24 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 114.92 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 94.07 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 52.82 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 204.57 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 83.80 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 149.95 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 135.79 Bn |
| Mar 31, 2026 | 135.21 Bn |
| Dec 31, 2025 | 133.93 Bn |
| Sep 30, 2025 | 135.54 Bn |
| Jun 30, 2025 | 136.67 Bn |
| Mar 31, 2025 | 135.66 Bn |
| Dec 31, 2024 | 139.29 Bn |
| Sep 30, 2024 | 142.68 Bn |
| Jun 30, 2024 | 145.41 Bn |
| Mar 31, 2024 | 141.79 Bn |
| Dec 31, 2023 | 135.47 Bn |
| Sep 30, 2023 | 135.79 Bn |
| Jun 30, 2023 | 134.96 Bn |
| Mar 31, 2023 | 136.67 Bn |
| Dec 31, 2022 | 140.07 Bn |
| Sep 30, 2022 | 142.26 Bn |
| Jun 30, 2022 | 143.20 Bn |
| Mar 31, 2022 | 144.87 Bn |
| Dec 31, 2021 | 147.69 Bn |
| Sep 30, 2021 | 148.42 Bn |